Research

Optimizing Anti–Tumor Necrosis Factor Inhibitor Therapy in Uveitis

AAO Journal5d ago1 min read

The introduction of tumor necrosis factor (TNF)-α inhibitors has successfully transformed the management of noninfectious uveitis over the past 2 decades. The Adalimumab in active and inactive non-infectious uveitis (VISUAL) trials established adalimumab as the first and currently only anti-TNF therapy approved for noninfectious intermediate uveitis, posterior uveitis, and panuveitis, demonstrating effective corticosteroid-sparing disease control in both active and inactive disease.1,2 Subsequent studies have served to refine our understanding of the role of adalimumab in uveitis management.

Read full article on AAO Journal

AI Summary

Quick Take

Adalimumab remains the only FDA-approved anti-TNF therapy for noninfectious intermediate, posterior, and panuveitis, a status solidified by the landmark VISUAL trials. Over the last two decades, it has fundamentally changed the treatment landscape by providing a reliable corticosteroid-sparing option for managing both active and inactive disease states.

Why It Matters

For years, the management of noninfectious uveitis was heavily reliant on long-term corticosteroids, which carry a significant burden of ocular and systemic side effects. The shift toward TNF-α inhibitors represents a move toward targeted immunomodulatory therapy that preserves vision while minimizing steroid toxicity. As the only approved agent in its class for these specific uveitis subtypes, adalimumab is the cornerstone of modern treatment for patients who fail first-line therapies or require long-term maintenance.

Key Findings

The VISUAL trials established adalimumab as an effective treatment for maintaining disease control in both active and inactive noninfectious uveitis.
Adalimumab is currently the only anti-TNF therapy with specific regulatory approval for intermediate uveitis, posterior uveitis, and panuveitis.
The therapy serves as a primary corticosteroid-sparing agent, allowing for reduced reliance on systemic steroids while preventing inflammatory flares.
Two decades of clinical data have shifted the management paradigm from reactive symptom control to proactive disease modification using TNF-α inhibitors.

Practice Implications

Clinicians should consider adalimumab early in the treatment course for patients with noninfectious intermediate, posterior, or panuveitis who require chronic steroid therapy. Because the drug is effective in maintaining quiescence in previously inactive disease, it should be viewed as a long-term management tool rather than just an acute intervention.

Who's Affected

Uveitis SpecialistsMedical Retina SpecialistsComprehensive Ophthalmologists

What's Next

While adalimumab is the current gold standard for anti-TNF therapy in uveitis, ongoing research continues to refine dosing strategies and explore the long-term comparative efficacy of other emerging biologics and biosimilars.

Evidence StrengthStrong

AI-generated summary — always read the original source for full context

Discussion

No comments yet. Be the first to share your thoughts.